
这个市场不值得进入。它不是新机会,而是已经进入明显拥挤、利润被压缩的状态:新品牌成功率只有44.44%,失败率53.85%,最近一批新品里也有57.14%没有跑出来,说明竞争在变难,不是在变简单。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
结论很明确:这个市场可以进,但只适合小预算、做差异化的新品牌;对想靠低价硬拼的卖家来说,已经接近价格战区。 用户预算 50万CNY 足够覆盖一条新品的前期铺货、头程和投放,而且明显高于可盈利新品的入场级别;但这笔钱不包含长期研发、品牌和认证,若走老款同质化路线,后续还会继续烧钱。
证据上,市场不是完全拥挤,但竞争强、且老品牌压制明显。 新品牌新品盈利率只有40%,非盈利率53.33%;老品牌新品盈利率50%,非盈利率同样是50%,说明不是所有新品都能赚钱,且老品牌占到新产品样本的44.44%,新品牌占主导的“增量红利”并不强。再看具体样本,HOMENURSE 用约2.24万CNY预算做出2个盈利新品,B0GLGWT5J2 和 B0GLGBHR24 的利润率分别是28.38%和28.5%,月收入合计约90.29万CNY;ProTraverce 只有1个盈利新品 B0GZZ5QF1P,利润率17.39%,26条评论、月收入约33.80万CNY,但它还有1个亏损新品 B0H7J48S6P,说明新品牌并不是随便上就能成。对大品牌来说,Drive Medical 这类老牌虽然月收入高,但其样本里0%新品盈利,且 B000MMC6EE 利润率是-55.58%,说明旧款大牌也有明显结构性亏损;真正值得跟的是有差异化功能的产品,比如 B0FNR41KMJ(单手折叠+加宽底座,151条评论,月收入约52.18万CNY)和 B0DGK8SPD4(前置篮筐+收纳袋,453条评论,月收入约41.34万CNY),这些都不是纯通用款。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不建议进入。它不是单纯“有竞争”,而是已经明显进入价格战式拥挤状态:新品牌成功率只有40%,新品牌新品失败率却高达53.33%,而且大量新进入者都在用非常接近的标准款做微调,差异化空间很窄。
从结果看,能赚钱的不是“普通助行器”,而是做出明确场景差异的产品;但失败样本也很多,说明这类机会已经偏向少数强执行者,而不是适合大多数人轻松切入的市场。
这个市场不值得进入。 新品牌并没有形成真正的低门槛机会,反而是中高利润被少数品牌和高投入新品占住;对小商家来说,想靠正常打法切入,成功概率不高。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0GLGBHR24 | HOMENURSE | 2026-04-12 | Yes | $82.04 | 700pcs | $57428.0 | 28.5% | $16366.98 |
![]() | B0FNR41KMJ | noerishia | 2025-08-26 | Yes | $65.22 | 800pcs | $52176.0 | 24.72% | $12897.91 |
![]() | B0D6W69619 | Loyoda | 2024-08-15 | Yes | $50.51 | 1000pcs | $50510.0 | 18.74% | $9465.58 |
![]() | B0GLGWT5J2 | HOMENURSE | 2026-04-12 | Yes | $82.15 | 400pcs | $32860.0 | 28.38% | $9325.67 |
![]() | B0DGK8SPD4 | Loyoda | 2024-12-04 | Yes | $59.06 | 700pcs | $41342.0 | 20.9% | $8640.48 |
![]() | B0DT43QNN8 | Loyoda | 2025-03-18 | Yes | $56.46 | 700pcs | $39522.0 | 19.72% | $7793.74 |
![]() | B0FB99SYL4 | HOLYHEAL | 2025-08-06 | Yes | $51.17 | 800pcs | $40936.0 | 17.09% | $6995.97 |
![]() | B0DZCMNJWM | WHLICKS | 2025-03-06 | Yes | $57.57 | 600pcs | $34542.0 | 14.1% | $4870.43 |
![]() | B0FD9G4ZR6 | HOLYHEAL | 2025-08-06 | Yes | $53.53 | 400pcs | $21412.0 | 18.86% | $4038.31 |
![]() | B0C18YND12 | DELOG | 2023-04-02 | Yes | $62.82 | 300pcs | $18846.0 | 16.25% | $3062.48 |
![]() | B0G254GM34 | HOLYHEAL | 2026-01-03 | Yes | $60.67 | 200pcs | $12134.0 | 19.62% | $2380.7 |
![]() | B0DGL6DZP9 | Loyoda | 2025-09-18 | Yes | $54.55 | 200pcs | $10910.0 | 20.46% | $2232.19 |
![]() | B0DG8VMFX6 | Loyoda | 2024-10-18 | Yes | $52.41 | 300pcs | $15723.0 | 10.26% | $1613.18 |
![]() | B0GGQ8GJZJ | HOMLAND | 2026-01-14 | Yes | $51.9 | 300pcs | $15570.0 | 10.05% | $1564.79 |
![]() | B0FJ2F1XP8 | Agrish | 2025-10-28 | Yes | $73.63 | 100pcs | $7363.0 | 19.52% | $1437.26 |
![]() | B0FHWFCJ6Y | HOLYHEAL | 2025-10-07 | Yes | $63.66 | 100pcs | $6366.0 | 22.48% | $1431.08 |
![]() | B0FMDHGY4B | WHLICKS | 2025-09-04 | Yes | $64.41 | 100pcs | $6441.0 | 20.35% | $1310.75 |
![]() | B0FHWH93MB | HOLYHEAL | 2025-09-27 | Yes | $60.0 | 100pcs | $6000.0 | 20.67% | $1240.2 |
![]() | B0FMDMKHND | WHLICKS | 2025-09-04 | Yes | $63.31 | 100pcs | $6331.0 | 17.49% | $1107.3 |
![]() | B0DNW6KKRK | Loyoda | 2025-01-15 | Yes | $54.89 | 100pcs | $5489.0 | 13.21% | $725.1 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
![]() | B0GLGBHR24 | HOMENURSE | 2026-04-12 | Yes | $82.04 | 700pcs | $57428.0 | 28.5% | $16366.98 |
![]() | B0FNR41KMJ | noerishia | 2025-08-26 | Yes | $65.22 | 800pcs | $52176.0 | 24.72% | $12897.91 |
![]() | B0GLGWT5J2 | HOMENURSE | 2026-04-12 | Yes | $82.15 | 400pcs | $32860.0 | 28.38% | $9325.67 |
![]() | B0G254GM34 | HOLYHEAL | 2026-01-03 | Yes | $60.67 | 200pcs | $12134.0 | 19.62% | $2380.7 |
![]() | B0DGL6DZP9 | Loyoda | 2025-09-18 | Yes | $54.55 | 200pcs | $10910.0 | 20.46% | $2232.19 |
![]() | B0GGQ8GJZJ | HOMLAND | 2026-01-14 | Yes | $51.9 | 300pcs | $15570.0 | 10.05% | $1564.79 |
![]() | B0FJ2F1XP8 | Agrish | 2025-10-28 | Yes | $73.63 | 100pcs | $7363.0 | 19.52% | $1437.26 |
![]() | B0FHWFCJ6Y | HOLYHEAL | 2025-10-07 | Yes | $63.66 | 100pcs | $6366.0 | 22.48% | $1431.08 |
![]() | B0FMDHGY4B | WHLICKS | 2025-09-04 | Yes | $64.41 | 100pcs | $6441.0 | 20.35% | $1310.75 |
![]() | B0FHWH93MB | HOLYHEAL | 2025-09-27 | Yes | $60.0 | 100pcs | $6000.0 | 20.67% | $1240.2 |
![]() | B0FMDMKHND | WHLICKS | 2025-09-04 | Yes | $63.31 | 100pcs | $6331.0 | 17.49% | $1107.3 |
![]() | B0GZZ5QF1P | ProTraverce | 2026-06-23 | Yes | $67.59 | 50pcs | $3379.5 | 17.39% | $587.7 |
这个市场目前不值得进入,属于明显的高竞争、接近价格战的环境。 新品整体可盈利率只有44.44%,但新上市产品里仍有53.85%不赚钱;更关键的是,成功几乎都集中在“基于旧款做功能微改”的路线,说明新品牌要想活下来,不能做普通款,必须做明确差异化,而且预算远不止初期铺货钱。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
这个市场不值得进入,已经进入高风险竞争区。 近两年新品牌不是在爆发式涌入(全年仅看到6个新品牌成功、8个失败的新品牌样本),但最近一批新产品的成功率只有42.86%,失败率57.14%,而且2026年里失败样本明显增多,说明竞争正在变难,不是变容易。
证据很直接:价格战和入场门槛都不低。 当前市场整体可识别产品里,盈利占比只有43.14%,新上新产品盈利占比44.44%,这不算健康;按入场时间看,2026年的样本里有9个产品落在“无法确认盈利/不够成熟”的区间,说明很多新品还没跑出来。单个可参考的新品牌成功案例是 noerishia 的 B0FNR41KMJ,利润率24.7%,近月销量800,月营收约52,176美元,早期投入约38,145.87美元,其中广告约8,579.01美元;HOMENURSE 的 B0GLGWT5J2 / B0GLGBHR24 也各自跑出盈利,但它们都偏向在成熟母体上做功能差异化,不是低成本随便切入就能复制。反过来,VOCIC 的 B0G4ZQBPMT、B0G9QTVGJL,以及 HOMLAND 的 B0H2YC22PG、B0GGQHM62N 都是新品牌失败样本,说明新品牌并不稳定。
对你最重要的结论:小生意别进,大品牌也不该现在进。 你的预算是50万人民币,表面上能覆盖单个ASIN启动,但市场里一个可参考的新产品早期投入已经到约38,146美元量级,且这还没算长期品牌、研发和认证成本;所以这个盘子对小品牌太重,对大品牌也没有足够好的胜率支撑。若硬要看案例,big brand 可跟的老牌样本是 Drive Medical 的 B001HOM4U2、Loyoda 的 B0DGK8SPD4;small business 只能看真正新品牌里少数白帽成功款 noerishia 的 B0FNR41KMJ、Agrish 的 B0FJ2F1XP8、HOLYHEAL 的 B0FHWFCJ6Y / B0GGQ8GJZJ,但这些成功并不代表现在还能低成本复制。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 2 | 0 | 0 | 2 | 5 | 0 | 0 | 2 |
| 2026 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 9 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/8 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 |
| 2025/10 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| 2025/11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/12 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/1 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 1 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/4 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/6 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| 2026/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |